<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04457089</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2020-03-Rimel-STOV</org_study_id>
    <nct_id>NCT04457089</nct_id>
  </id_info>
  <brief_title>Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer</brief_title>
  <official_title>Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bobbie Jo Rimel, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm pilot trial to evaluate the feasibility of using a simvastatin&#xD;
      intervention, and to evaluate its effects on cancer progression, among 20 patients with&#xD;
      platinum-sensitive ovarian cancer, treated with carboplatin and liposomal doxorubicin at&#xD;
      Cedars-Sinai Medical Center.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study of statin therapy to examine the feasibility of simvastatin use to&#xD;
      reduce disease progression in 20 patients with platinum-sensitive ovarian cancer at&#xD;
      Cedars-Sinai Medical Center. This study will focus on patients with recurrent platinum&#xD;
      sensitive ovarian cancer to increase the likelihood that this population will experience&#xD;
      recurrent disease during the 6-month intervention and follow-up. In addition, this population&#xD;
      of patients has a narrow range of standard of care carboplatin doublet combinations that are&#xD;
      prescribed, enabling the investigators to create a more homogenous study population. Given&#xD;
      their high risk of developing recurrent disease, women with platinum sensitive ovarian&#xD;
      cancer, have the potential to derive the maximum benefit from an intervention that could&#xD;
      delay disease progression and enhance survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completion of the simvastatin intervention with at least 85% compliance</measure>
    <time_frame>From Cycle 1 Day 1 until Cycle 6 Day 28 (each cycle is 28 days)</time_frame>
    <description>Percentage of patients who complete the simvastatin intervention with at least 85% compliance during Carboplatin and Doxil chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response by CA125</measure>
    <time_frame>From baseline until 12 months</time_frame>
    <description>Change in serum level of CA125</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From baseline until 12 months</time_frame>
    <description>Duration until disease progression or death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Recurrent Ovarian Cancer</condition>
  <condition>Platinum-sensitive Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 40mg</intervention_name>
    <description>Simvastatin 40mg by mouth nightly for approximately 6 months during treatment with carboplatin and liposomal doxorubicin</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recurrent platinum sensitive ovarian cancer, all histologies (serous, endometrioid,&#xD;
             mucinous, clear cell). Platinum sensitivity defined as â‰¥ 6 months since last platinum&#xD;
             treatment.&#xD;
&#xD;
          -  No contraindication to carboplatin and/or liposomal doxorubicin or simvastatin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or current use of any statin medication&#xD;
&#xD;
          -  Current systemic use of medications known to interact with statins&#xD;
&#xD;
          -  Current use of any other investigational agents&#xD;
&#xD;
          -  Liver disease, active cirrhosis&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  History of chronic myopathy&#xD;
&#xD;
          -  Prior cancer other than ovarian cancer or non-melanomatous skin cancers&#xD;
&#xD;
          -  Known active infection with HIV&#xD;
&#xD;
          -  Current excessive alcohol consumption (average alcohol consumption of more than 5&#xD;
             drinks per day)&#xD;
&#xD;
          -  Prior exposure to doxorubicin or liposomal doxorubicin&#xD;
&#xD;
          -  Hemoglobin A1C &gt;8.0%&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bobbie Jo Rimel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cynthia Martin</last_name>
    <phone>310-423-2276</phone>
    <email>Cynthia.Martin@cshs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Martin</last_name>
      <phone>310-423-2276</phone>
      <email>Cynthia.Martin@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Bobbie Jo Rimel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Goodman, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Walsh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristin Taylor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 25, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Bobbie Jo Rimel, MD</investigator_full_name>
    <investigator_title>Oncologist</investigator_title>
  </responsible_party>
  <keyword>simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

